Head-to-head evidence
QLM3003 vs upadacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK · full Atopic Dermatitis pipeline
QLM3003
Developed by Qilu Pharmaceutical
NCT06058000 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and enrolled 120 participants, with a clinical disease-activity endpoint (EASI-75). However, no primary endpoint results or statistical comparison are available, so the trial provides well-designed but currently incomplete evidence.
Next expected readout: March 2027 · NCT06880276 (registry estimate)
upadacitinib · Rinvoq
Marketed by AbbVie
NCT03607422 · Phase 3 · completed
Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).
Next expected readout: January 2027 · NCT06701331 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: QLM3003's landscape · upadacitinib's landscape